Prim (XMAD:PRM) Risk Assessment


XMAD:PRM Prim SA XMAD:PRM
76 GF Score
Price €13.40
GF Value €7.52
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Prim Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Prim is: Low Risk: Strong fundamentals, worth long-term holding.

Prim  (XMAD:PRM) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Prim Risk Assessment Related Terms

XMAD:PRM vs ISRG, BDX, MDLN: Risk Assessment Comparison

For the Medical Instruments & Supplies subindustry, Prim's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prim Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Prim's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Prim's Risk Assessment falls into.


XMAD:PRM
76GF Score
Prim SA XMAD:PRM
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Prim (XMAD:PRM) Overvalued in 2026?

Based on GuruFocus' analysis, Prim stock appears to be overvalued. The current stock price of €13.40 is trading 78.2% above its estimated GF Value™ of €7.52. GuruFocus considers Prim to be Significantly Overvalued.

Key valuation signals for XMAD:PRM:

  • Risk Assessment:
  • GF Value™: €7.52 vs. price of €13.40 (78.2% above fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the XMAD:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prim Business Description

Other Exchanges 0FP0:UK5P1:Germany
Address Calle F, numero 15, Poligono Industrial 1, Mostoles, Madrid, ESP, 28938
Prim SA is engaged in the provision of hospital supplies. The company is in a hospital and orthopedic supplies and materials for physiotherapy, thalassotherapy, thermal therapy, rehabilitation, geriatrics, as well as daily living aids. Prim work across a division of healthcare units such as Operating Theatres; Pain Management Centres; Plastic Surgery; Endosurgery and Cardiovascular.
76GF Score

Get the complete analysis for XMAD:PRM

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.40
Price
€7.52
GF Value